EU/3/20/2252

Table of contents

About

On 28 February 2020, orphan designation EU/3/20/2252 was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor for B-cell maturation antigen (also known as JNJ-68284528 or LCAR-B38M CAR-T cells) for the treatment of multiple myeloma.

Key facts

Active substance
Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor for B-cell maturation antigen
Disease / condition
Treatment of multiple myeloma
Date of first decision
28/02/2020
Outcome
Positive
EU designation number
EU/3/20/2252

Sponsor's contact details

Janssen-Cilag International N.V.
Turnhoutseweg 30
2340 Beerse
Antwerp
Belgium
Tel: +31621385718
E-mail: nreymond@its.jnj.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating